Literature DB >> 27341988

Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.

Frank E Chang1, Stephanie A Beall2, Jeris M Cox3, Kevin S Richter4, Alan H DeCherney3, Michael J Levy4.   

Abstract

OBJECTIVE: To compare outcomes of in vitro fertilization (IVF) cycles with adequate versus inadequate response to the gonadotropin-releasing hormone (GnRH) agonist trigger rescued with the use of human chorionic gonadotropin (hCG) retrigger, and to identify risk factors associated with an inadequate trigger.
DESIGN: Retrospective cohort study.
SETTING: Private practice. PATIENT(S): Women at high risk for ovarian hyperstimulation syndrome who underwent an autologous IVF cycle and used GnRH agonist to trigger oocyte maturation before oocyte retrieval. INTERVENTION(S): Patients were triggered with GnRH agonist for final oocyte maturation before retrieval. Patients with an inadequate response, defined by low post-trigger serum LH and P concentrations or failure to recover oocytes after aspiration of several follicles, were retriggered with hCG. MAIN OUTCOME MEASURE(S): Number of oocytes retrieved, fertilization rate, clinical pregnancy, and live birth. RESULT(S): Two percent of patients triggered with GnRH agonist had an inadequate response and were retriggered with hCG. There was no statistically significant difference in clinical outcomes between the cycles that were retriggered with hCG and successful GnRH agonist triggers. Low body mass index, low baseline LH, and higher total dosage of gonadotropins required for stimulation were associated with an increased risk of having an inadequate response to the GnRH agonist trigger. CONCLUSION(S): A small minority of patients triggered with GnRH agonist had an inadequate response. Rescheduling of oocyte retrieval after hCG retrigger yielded similar IVF outcomes. Evaluation of trigger response based on serum LH and P concentrations is time dependent. Patient characteristics suggestive of hypothalamic hypofunction were predictive of an inadequate response to the GnRH agonist trigger.
Copyright © 2016 American Society for Reproductive Medicine. All rights reserved.

Entities:  

Keywords:  Gonadotropin-releasing hormone (GnRH) agonist; human chorionic gonadotropin (hCG); in vitro fertilization (IVF); leuprolide acetate; retrigger

Mesh:

Substances:

Year:  2016        PMID: 27341988     DOI: 10.1016/j.fertnstert.2016.06.013

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  9 in total

1.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

Review 2.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

Review 3.  Prediction, assessment, and management of suboptimal GnRH agonist trigger: a systematic review.

Authors:  Hadas Ganer Herman; Eran Horowitz; Yossi Mizrachi; Jacob Farhi; Arieh Raziel; Ariel Weissman
Journal:  J Assist Reprod Genet       Date:  2022-03-19       Impact factor: 3.412

4.  Empty Follicle Syndrome Following GnRHa Trigger in PCOS Patients Undergoing IVF Cycles.

Authors:  Krishna Deepika; Davuluri Sindhuma; Bijlani Kiran; Nair Ravishankar; Praneesh Gautham; Rao Kamini
Journal:  J Reprod Infertil       Date:  2018 Jan-Mar

5.  Gonadotropin levels at the start of ovarian stimulation predict normal fertilization after hCG re-trigger in GnRH antagonist cycles.

Authors:  Hiroya Kitasaka; Mikiko Tokoro; Masae Kojima; Noritaka Fukunaga; Yoshimasa Asada
Journal:  Reprod Med Biol       Date:  2020-12-18

6.  Gonadotropin-Releasing Hormone Agonist Versus Recombinant Human Chorionic Gonadotropin Triggering in Fertility Preservation Cycles.

Authors:  Einat Haikin Herzberger; Sabaa Knaneh; Hadar Amir; Adi Reches; Dalit Ben-Yosef; Yael Kalma; Foad Azem; Nivin Samara
Journal:  Reprod Sci       Date:  2021-06-02       Impact factor: 3.060

7.  Oocyte cryopreservation in a transgender man on long-term testosterone therapy: a case report.

Authors:  Jenna Gale; Bryden Magee; Amanda Forsyth-Greig; Hasina Visram; Aaron Jackson
Journal:  F S Rep       Date:  2021-02-20

8.  Self-Detection of the LH Surge in Urine After GnRH Agonist Trigger in IVF-How to Minimize Failure to Retrieve Oocytes.

Authors:  Mauro Cozzolino; Sonia Matey; Abigail Alvarez; Mónica Toribio; Verónica López; Marta Perona; Elizabet Henzenn; Manuel Piró; Peter Humaidan; Juan A Garcia-Velasco
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-21       Impact factor: 5.555

Review 9.  The Future of Cryopreservation in Assisted Reproductive Technologies.

Authors:  Ernesto Bosch; Michel De Vos; Peter Humaidan
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-20       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.